Discover
AKTX
Akari Therapeutics, Plc
9.16
1 x 10.29
8 x 9.78
bid
ask
-
0.71
7.24%
5 @ 05:02 PM
9.20 +0.04 (0.44%)
| Ytd | -20.76% | |
| 1y | -71.38% |
9.16
day range
10.13
3.06
52 week range
44.80
| Open | 9.76 | Prev Close | 9.88 | Low | 9.16 | High | 10.13 | Mkt Cap | 17.83M |
| Vol | 63.65K | Avg Vol | 75.78K | EPS | N/A | P/E | N/A | Forward P/E | -0.29 |
| Beta | 0.95 | Short Ratio | 1.92 | Inst. Own | 0.51% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-22 | 50-d Avg | 9.47 | 200-d Avg | 9.58 | 1yr Est | 80.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-05-06 | 2023-12 | 0 | N/A | N/A | N/A |
| 2023-10-03 | 2023-06 | 0 | N/A | N/A | N/A |
| 2023-07-19 | 2023-03 | 0 | N/A | N/A | N/A |
| 2023-05-15 | 2022-12 | 0 | N/A | N/A | N/A |
| 2023-01-06 | 2022-09 | 0 | N/A | N/A | N/A |
| 2022-09-27 | 2022-06 | 0 | -2 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-04-30 | DICICCO WENDY FRANCES | Chief Financial Officer | 158.47M | Stock Award(Grant) |
| 2024-06-27 | PATEL SAMIR RASHMIKANT | Director | 3.50B | Stock Award(Grant) |
| 2024-12-01 | PRUDO-CHLEBOSZ RAYMOND M.D. | Director | 4.92B | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Omnia Family Wealth, LLC | 87.63K | 85.88K | 0.33% |
| 2024-09-29 | Citadel Advisors Llc | 33.26K | 32.59K | 0.13% |
| 2024-09-29 | Cerity Partners LLC | 23.64K | 23.17K | 0.09% |
| 2024-09-29 | Renaissance Technologies, LLC | 18.07K | 17.71K | 0.07% |
| 2024-09-29 | Cresset Asset Management, LLC | 18.41K | 18.04K | 0.07% |
| 2024-09-29 | Cornerstone Planning Group LLC | 5.00 | 4.00 | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 1.51K | 1.48K | 0.01% |
Split
| Split | Date |
|---|---|
| 1 : 40 | 2026-03-31 |
| 1 : 20 | 2023-08-21 |
| 1 : 10 | 2015-09-17 |